DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Allo-hMSCs; Ambrisentan; Autologous (self) mononuclear cells derived from umbilical cord blood; Autologous Human Placental Cord Blood Mononuclear Cells; Autologous Umbilical Cord Blood; Autologous cell-based delivery; Bosentan; C-kit+ cells; Curosurf; Erythropoetin; Longeveron Mesenchymal Stem Cells; METHYLPREDNISOLONE SODIUM SUCCINATE; MPC; Maternal Hyperoxygenation; Maternal hyperoxygenation; Methylprednisolone; Metyyliprednisoloninatriumsuksinaatti; Nitrogen; Normal saline; Oxandrolone; Procedure: Stage II Surgical repair; Rexlemestrocel-L; Sham; Sildenafil; Solu-Medrol; Solu-medrol; Tracleer; Vitamin C

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03136835 (ClinicalTrials.gov)	February 2, 2018	28/10/2015	Maternal Hyperoxygenation in Congenital Heart Disease	Maternal Hyperoxygenation in Congenital Heart Disease	Hypoplastic Left Heart Syndrome	Drug: Maternal Hyperoxygenation	The Hospital for Sick Children	NULL	Recruiting	18 Years	N/A	Female	20	Phase 1;Phase 2	Canada
2	NCT03147014 (ClinicalTrials.gov)	January 1, 2016	4/5/2017	Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease	Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease	Hypoplastic Left Heart Syndrome;Aortic Coarctation;Atrial Septal Aneurysm	Biological: Maternal hyperoxygenation	Beijing Anzhen Hospital	NULL	Recruiting	N/A	N/A	Female	600	N/A	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03136835
(ClinicalTrials.gov)

February 2, 2018

28/10/2015

Maternal Hyperoxygenation in Congenital Heart Disease

Hypoplastic Left Heart Syndrome

Drug: Maternal Hyperoxygenation

The Hospital for Sick Children

NULL

Recruiting

18 Years

N/A

Female

Phase 1;Phase 2

Canada

NCT03147014
(ClinicalTrials.gov)

January 1, 2016

4/5/2017

Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease

Hypoplastic Left Heart Syndrome;Aortic Coarctation;Atrial Septal Aneurysm

Biological: Maternal hyperoxygenation

Beijing Anzhen Hospital

NULL

Recruiting

N/A

Female

600

N/A

China